Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by princeofcuton Aug 18, 2015 4:28pm

75 Views

Post# 24029290

RE:RE:RE:re: Leadership Matters discussion, ETC-1002 & Don

ronny, ronny, ronny...stop making stuff up ESPR ain't down "another $3 after hours"...but irrelevant as key is market cap (you should know that if you manage money) and ESPR is $1.4B which is astonishing and about a gillizion in Cnd $ (have we broke below $0.50 yet) and so in CND dollar about $2B still vs. RVX at $163M (and it seems the gap is growing)...208 supposedly has a bigger market opp so why the disconnect...PS todate as far as i know ESPR has foccused 100% only on the US market, imagine if they started to crow about world wide

Bullboard Posts

HPQ Silicon updates shareholders on Fumed Silica Reactor developments